Pro Medicus Ltd banner

Pro Medicus Ltd
F:PMC

Watchlist Manager
Pro Medicus Ltd Logo
Pro Medicus Ltd
F:PMC
Watchlist
Price: 125.12 EUR 0.08% Market Closed
Market Cap: €171.7B

Wall St Price Targets

PMC Price Targets Summary
Pro Medicus Ltd

Wall Street analysts forecast PMC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PMC is 149.75 EUR with a low forecast of 86.09 EUR and a high forecast of 199.34 EUR.

Lowest Forecast
Price Target
86.09 EUR
31% Downside
Average Forecast
Price Target
149.75 EUR
20% Upside
Highest Forecast
Price Target
199.34 EUR
59% Upside
Pro Medicus Ltd Competitors:
Price Targets
VEEV
Veeva Systems Inc
32% Upside
WHF
WhiteHorse Finance Inc
22% Upside
AEVA
Aeva Technologies Inc
22% Upside
DRT
DIRTT Environmental Solutions Ltd
82% Upside

Revenue
Forecast

26% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
26% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 26%. The projected CAGR for the next 8 years is 16%.

Gross Profit
Forecast

26% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
26% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

Over the last 13 years, the compound annual growth rate for Gross Profit has been 26%. The projected CAGR for the next 8 years is 16%.

Operating Income
Forecast

67% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
67% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 13 years, the compound annual growth rate for Operating Income has been 67%. The projected CAGR for the next 8 years is 12%.

Pre-Tax Income
Forecast

48% / Year
Past Growth
29% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
48% / Year
Past Growth
29% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 48%. The projected CAGR for the next 3 years is 29%.

Net Income
Forecast

38% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
38% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 38%. The projected CAGR for the next 8 years is 13%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is PMC's stock price target?
Price Target
149.75 EUR

According to Wall Street analysts, the average 1-year price target for PMC is 149.75 EUR with a low forecast of 86.09 EUR and a high forecast of 199.34 EUR.

What is the Revenue forecast for Pro Medicus Ltd?
Projected CAGR
16%

Over the last 13 years, the compound annual growth rate for Revenue has been 26%. The projected CAGR for the next 8 years is 16%.

What is the Gross Profit forecast for Pro Medicus Ltd?
Projected CAGR
16%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 26%. The projected CAGR for the next 8 years is 16%.

What is the Operating Income forecast for Pro Medicus Ltd?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Operating Income has been 67%. The projected CAGR for the next 8 years is 12%.

What is the Pre-Tax Income forecast for Pro Medicus Ltd?
Projected CAGR
29%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 48%. The projected CAGR for the next 3 years is 29%.

What is the Net Income forecast for Pro Medicus Ltd?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Net Income has been 38%. The projected CAGR for the next 8 years is 13%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett